STOCK TITAN
  1. Home
  2. News
  3. VIRX

Viracta Therapeutics Inc - VIRX STOCK NEWS

Welcome to our dedicated page for Viracta Therapeutics news (Ticker: VIRX), a resource for investors and traders seeking the latest updates and insights on Viracta Therapeutics stock.

Viracta Therapeutics, Inc. (symbol: VIRX) is a precision oncology company dedicated to developing innovative therapies targeting virus-associated cancers, particularly those linked to the Epstein-Barr Virus (EBV). The company is pioneering a proprietary viral gene activation therapy aimed at treating serious virus-associated diseases.

Viracta is currently conducting three clinical trials for its combination product candidate, designed as a potential treatment for relapsed/refractory EBV-positive lymphoma. This product candidate integrates nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), with valganciclovir, an FDA-approved antiviral drug used to treat cytomegalovirus (CMV) infections.

The company’s research focuses on advancing its Nana-val (nanatinostat and valganciclovir) therapy through various phases of clinical trials. Recent projects include the Phase 1b/2 study of Nana-val in recurrent/metastatic EBV+ nasopharyngeal carcinoma (NPC) and other EBV+ solid tumors.

Viracta Therapeutics is committed to delivering breakthrough treatments that address the unmet medical needs of patients with virus-associated malignancies. The company continues to establish partnerships and collaborations to enhance its research and development capabilities, ensuring a robust pipeline of innovative therapies.

For the latest updates and further information, please visit www.viracta.com.

News

Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

Rhea-AI Summary

Viracta Therapeutics, a clinical-stage precision oncology company, is set to present at the RBC Capital Markets Global Healthcare Conference. The event will feature the President and CEO, Mark Rothera, and the Chief Medical Officer, Dr. Darrel P. Cohen. The presentation is scheduled for May 14, 2024, at 11:00 a.m. EDT and will be available for live webcast and archived on the Viracta website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News

Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma

Rhea-AI Summary
Viracta Therapeutics reports positive topline results from Stage 1 of the NAVAL-1 trial in patients with relapsed or refractory EBV+ PTCL. Nana-val combination therapy shows an overall response rate of 50% and a complete response rate of 20% in the intent-to-treat population, with manageable safety profile. Data presented at 2024 Joint Annual Congress of Taiwan Society of Blood and Marrow Transplantation and The Hematology Society of Taiwan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.17%
Tags
none
-
News

Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan

Rhea-AI Summary
Viracta Therapeutics, Inc. (VIRX) announces topline Stage 1 data from NAVAL-1 trial of Nana-val in EBV+ peripheral T-cell lymphoma patients will be presented at a medical congress. The presentation will focus on the 'Kick and Kill' mechanism of action.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.82%
Tags
conferences
News

LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress

Rhea-AI Summary
LENZ Therapeutics, a late clinical-stage biopharmaceutical company, is set to debut on Nasdaq under the ticker symbol 'LENZ'. The company is advancing late-stage assets for presbyopia treatment, with topline data from Phase 3 CLARITY trials expected in April 2024. LENZ boasts a strong balance sheet with approximately $210 million in cash and cash equivalents, including $53.5 million from a concurrent PIPE financing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.35%
Tags
acquisition
-
News

Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Viracta Therapeutics, Inc. (VIRX) completes Stage 2 enrollment in NAVAL-1 trial of Nana-val for EBV+ lymphoma, expects topline results in Q2 2024. Strengthened balance sheet with $5.0 million non-dilutive proceeds, extending cash runway. Clinical trial updates, business developments, and financial results detailed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
earnings
-
News

Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial

Rhea-AI Summary
Viracta Therapeutics, Inc. completes Stage 2 enrollment for Nana-val in treating EBV-associated cancers. Topline results expected in Q2 and Q3 of 2024. FDA meeting planned for mid-2024 for potential accelerated approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.87%
Tags
none
News

Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Rhea-AI Summary
Viracta Therapeutics, Inc. (VIRX) announced the participation of its President and CEO, Mark Rothera, and Chief Medical Officer, Darrel P. Cohen, in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The webcast will be available on the company's website. The company focuses on precision oncology for virus-associated cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.68%
Tags
conferences
-
News

Viracta Therapeutics Provides Clinical Update and Outlook for 2024

Rhea-AI Summary
Viracta Therapeutics, Inc. (VIRX) provided a clinical update on Nana-val's clinical development in 2024, focusing on patients with relapsed or refractory EBV+ peripheral T-cell lymphoma and advanced EBV+ solid tumors. The company aims to complete enrollment of Stage 2 for the R/R EBV+ PTCL cohort in Q1 2024 and engage with the FDA on potential accelerated approval pathway by mid-2024. Additionally, they plan to determine the recommended Phase 2 dose and initiate Phase 2 in 2024 for patients with advanced EBV+ solid tumors. The company also highlighted recent clinical trial updates, including the completion of enrollment of Stage 1 in the R/R EBV+ PTCL cohort, initiation of the sixth dose cohort of patients with recurrent or metastatic EBV+ nasopharyngeal carcinoma, and the FDA granting an orphan drug designation to Nana-val for the treatment of NPC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
none
-
News

Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma

Rhea-AI Summary
Viracta Therapeutics, a precision oncology company (Nasdaq: VIRX), received the first orphan drug designation (ODD) for Nana-val in EBV+ solid tumors. This is the seventh ODD for Nana-val globally and the fifth granted by the FDA. The FDA granted ODD to Nana-val for the treatment of nasopharyngeal carcinoma (NPC), marking its first ODD in EBV+ solid tumors and outside of EBV-associated lymphomas. The company's President and CEO, Mark Rothera, expressed optimism about the interim data from the Phase 1b/2 study of Nana-val in patients with recurrent or metastatic EBV-positive nasopharyngeal carcinoma. The ODD provides various benefits, including potential market exclusivity, tax credits, reduced fees, and expedited drug development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6%
Tags
clinical trial
News

Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels

Rhea-AI Summary
Viracta Therapeutics, Inc. (Nasdaq: VIRX) announced encouraging Phase 1b/2 clinical trial data of Nana-val in patients with recurrent or metastatic Epstein-Barr virus-positive nasopharyngeal carcinoma (NPC) at the ESMO Asia Congress. The study showed two ongoing confirmed partial responses at higher dose levels, supporting the advancement and dose escalation of the study. Enrollment for the sixth dose cohort is underway, with plans to initiate a recommended Phase 2 dose-optimization cohort in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.08%
Tags
clinical trial

FAQ

What is the current stock price of Viracta Therapeutics (VIRX)?

The current stock price of Viracta Therapeutics (VIRX) is $0.0228 as of February 28, 2025.

What is the market cap of Viracta Therapeutics (VIRX)?

The market cap of Viracta Therapeutics (VIRX) is approximately 2.1M.

What does Viracta Therapeutics, Inc. specialize in?

Viracta Therapeutics specializes in developing therapies targeting virus-associated cancers, particularly those linked to the Epstein-Barr Virus.

What is nanatinostat?

Nanatinostat is a small molecule inhibitor of class I histone deacetylases (HDAC), used in Viracta's combination product candidate for treating EBV-positive cancers.

What is valganciclovir used for?

Valganciclovir is an FDA-approved antiviral drug used to treat and prevent cytomegalovirus (CMV) infections, and it's part of Viracta's combination product candidate.

What are the current projects of Viracta Therapeutics?

Viracta is conducting three clinical trials for its combination product candidate, focusing on the treatment of relapsed/refractory EBV-positive lymphoma.

What is the Nana-val therapy?

Nana-val is a combination of nanatinostat and valganciclovir, currently under investigation as a treatment for EBV-associated cancers.

Where can I find more information about Viracta Therapeutics?

You can visit their website at www.viracta.com for more information and the latest updates.

Who is the contact person for investor relations at Viracta?

Ashleigh Barreto is the Head of Investor Relations & Corporate Communications at Viracta Therapeutics.

What types of cancers is Viracta targeting?

Viracta is primarily targeting cancers associated with the Epstein-Barr Virus, including EBV-positive lymphoma and other EBV+ solid tumors.

How does Viracta's viral gene activation therapy work?

Viracta's therapy aims to activate viral genes to trigger a therapeutic response against virus-associated malignancies.

What is the significance of the Phase 1b/2 study of Nana-val?

This study investigates the efficacy of Nana-val in treating recurrent/metastatic EBV+ nasopharyngeal carcinoma (NPC) and other EBV+ solid tumors.
Stock VIRX logo
Viracta Therapeutics Inc

Nasdaq:VIRX

VIRX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

VIRX Stock Data

2.12M
38.65M
2.84%
50.06%
6.83%
Biotechnology
Pharmaceutical Preparations
Link
United States
CARDIFF